RT Journal Article
SR Electronic
T1 Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.10.19016188
DO 10.1101/2020.02.10.19016188
A1 Diallo, Ousmane Oumou
A1 Baron, Sophie Alexandra
A1 Dubourg, Gregory
A1 Chaudet, Hervé
A1 Halfon, Philippe
A1 Camiade, Sabine
A1 Comte, Béatrice
A1 Joubert, Stéphanie
A1 François, Arnaud
A1 Seyral, Philippe
A1 Parisot, François
A1 Casalta, Jean-Paul
A1 Ruimy, Raymond
A1 Maruejouls, Christophe
A1 Achiardy, Jean-Christophe
A1 Burignat, Sophie
A1 Carvajal, Joseph
A1 Delaunay, Edouard
A1 Meyer, Sandra
A1 Levy, Pierre-Yves
A1 Roussellier, Patricia
A1 Brunet, Patrick
A1 Bosi, Claude
A1 Stolidi, Philippe
A1 Arzouni, Jean-Pierre
A1 Gay, Gisele
A1 Hance, Pierre
A1 Colson, Philippe
A1 Raoult, Didier
A1 Rolain, Jean-Marc
YR 2020
UL http://medrxiv.org/content/early/2020/02/11/2020.02.10.19016188.abstract
AB Introduction The burden of antibiotic resistance is currently estimated by mathematical modeling, without real count of resistance to key antibiotics. Here we report the real rate of resistance to key antibiotics in bacteria isolated from humans during a 5 years period in a large area in southeast in France.Methods We conducted a retrospective study on antibiotic susceptibility of 539,107 clinical strains isolated from hospital and private laboratories in south of France area from January 2014 to January 2019. The resistance rate to key antibiotics as well as the proportion of bacteria classified as Difficult-to-Treat (DTR) were determined and compared with the Mann-Whitney U test, the χ2 test or the Fisher’s exact test.Results Among 539,037 isolates, we did not observe any significant increase or decrease in resistance to key antibiotics for 5 years, (oxacillin resistance in Staphylococcus aureus, carbapenem resistance in enterobacteria and Pseudomonas aeruginosa and 3rd generation cephalosporin resistance in Escherichia coli and Klebsiella pneumoniae). However, we observed a significant decrease in imipenem resistance for Acinetobacter baumannii from 2014 to 2018 (24.19% to 12.27%; p=0.005) and a significant increase of ceftriaxone resistance in Klebsiella pneumoniae (9.9% to 24,03%; p=0.001) and Enterobacter cloacae (24,05% to 42,05%; p=0.004). Of these 539,037 isolates, 1,604 (0.3%) had a DTR phenotype.Conclusion Over a 5-year period, we did not observe a burden of AR in our region despite a high rate of antibiotic consumption in our country. These results highlight the need for implementation of real-time AR surveillance systems which use factual data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the “Investissements d’avenir” (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the supplementary files